- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | 629 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| 11.12.25 | NGM MARKET NOTICE: #25-119 Decision on delisting of Diagonal Bio AB from Nordic SME | 4 | Cision News | ||
| 11.12.25 | XFRA 9F1: AUSSETZUNG/SUSPENSION | 244 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDIAGONAL BIO AB... ► Artikel lesen | |
| 11.12.25 | NGM MARKET NOTICE: #25-118 Trading halt in Diagonal Bio AB | 5 | Cision News | ||
| 04.03.25 | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 348 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03.25 | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 277 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 07.02.25 | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 483 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 29.01.25 | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 194 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 13,260 | +10,50 % | Cathie Wood's ARK adds to Intellia stock holdings on January 15 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,212 | +7,04 % | PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research | ||
| ATAIBECKLEY | 3,990 | +2,31 % | AtaiBeckley N.V.: AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation | ||
| BIOMERIEUX | 104,20 | -1,33 % | BIOMERIEUX: bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies | ||
| BIO GREEN MED SOLUTION | 1,440 | +2,49 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 31,800 | +0,63 % | Broker tips: Close Brothers, BP, Genus | ||
| ANAPTYSBIO | 40,000 | 0,00 % | AnaptysBio, Inc.: Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology... ► Artikel lesen | |
| ABIONYX PHARMA | 3,810 | +2,01 % | ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA | Regulatory News:
Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,795 | 0,00 % | XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership | Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying... ► Artikel lesen | |
| AKESO | 12,700 | +0,79 % | CICC Predicts HSI to Add ZIJIN GOLD INTL/BEONE MEDICINES/PICC P&C/AKESO as New Constituents; STANCHART May Replace HANG SENG BANK | ||
| MEIRAGTX | 6,300 | -3,08 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| MAAT PHARMA | 5,260 | 0,00 % | MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis | IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,051 | +3,64 % | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| QIAGEN | 46,125 | -0,27 % | Qiagen: Neue Spekulationen | Bei Qiagen gibt es erneut Übernahmegerüchte. Angeblich werden strategische Optionen, darunter auch ein Verkauf, geprüft. Demnach sondiert der Aufsichtsrat das Interesse von möglichen Käufern. Es soll... ► Artikel lesen | |
| BIONTECH | 102,50 | +1,49 % | Milliardenhoffnung: BioNTech greift mit Krebsforschung neu an: Goldman Sachs löst Kursschub mit optimistischem Onkologie-Ausblick aus | Die US-Investmentbank Goldman Sachs hat die Aktie von BioNTech deutlich hochgestuft. Statt auf das abklingende Impfstoffgeschäft konzentriert sich die Bewertung nun auf die wachstumsstarke Pipeline... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,004 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.